BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spiers J, Brindley JH, Li W, Alazawi W. What’s new in non-alcoholic fatty liver disease? Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang N, Fan T, Zhao L, Li Y, Bao Y, Ma X, Mei Y, Wang Y, Liu Y, Deng H, Li Y, He H, Song D. Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR). European Journal of Medicinal Chemistry 2023;245:114886. [DOI: 10.1016/j.ejmech.2022.114886] [Reference Citation Analysis]
2 Eilam Y, Pintel N, Khattib H, Shagug N, Taha R, Avni D. Regulation of Cholesterol Metabolism by Phytochemicals Derived from Algae and Edible Mushrooms in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23. [PMID: 36430146 DOI: 10.3390/ijms232213667] [Reference Citation Analysis]
3 Kim HY, Yoo YH. The Role of STAMP2 in Pathogenesis of Chronic Diseases Focusing on Nonalcoholic Fatty Liver Disease: A Review. Biomedicines 2022;10:2082. [DOI: 10.3390/biomedicines10092082] [Reference Citation Analysis]